News & Events
Published On: 2/20/2020
TARGET-IBD Poster & Oral Presentation at ECCO
Earlier this month, TARGET attended the 15th annual Congress of European Crohn’s and Colitis Organisation (ECCO) event in Vienna, Austria. TARGET was selected to present two encores from the 2019 American College of Gastroenterology meeting.
The first was accepted as a poster, “Oral Mesalamine Use in Crohn’s Disease After Implementation of the American College of Gastroenterology Guidelines: A TARGET-IBD Cohort Study”. It was presented by Bruce Sands, MD, a TARGET-IBD steering committee Co-Chair and Chief of the Dr. Henry D. Janowitz Division of Gastroenterology at Mount Sinai.
The second was accepted as a digital oral presentation titled “Medication Use and Comorbidities Among Elderly as Compared to Younger Patients with Inflammatory Bowel Disease in the TARGET-IBD Cohort”. It was also presented by Dr. Sands.
The focus of the talk was on characterizing inflammatory bowel disease-related medications in elderly patients. Notable findings were that mesalamine use was the most common medication among patients over 65 years of age (even for Crohn’s disease patients), and that use of anti-tumor necrosis factor alpha medications decreased in patients in the older age groups when compared to patients under 30 years of age. The presentation was additionally honored as the Best Digital Oral Presentation of Session 3.
You can find all of the presented TARGET-IBD posters on our Publications page.
About Target RWE
Headquartered in Durham, NC, Target RWE is an innovative health evidence solutions company generating real-world evidence (RWE) and delivering regulatory-grade data to partners to advance clinical, medical, and commercial outcomes as well as to improve patient health guidelines and quality of care.
Target RWE has developed a turnkey health evidence solution which rapidly aggregates real-world data (RWD) from a large network of participating sites (academic and community) across the United States, Europe and other non-U.S. locations. Target RWE’s datasets are aggregated from various data sources including registries, electronic medical records, patient outcomes measures, biospecimen analyses, and claims databases. Whether partners need consulting services, datasets, support for custom solutions or access to a large biorepository of disease agnostic patient samples, Target RWE strives to be the preferred choice.
For more information, visit www.targetrwe.com.
984.234.0268 ext 205
07/22/2021Target RWE HBV Research on Antiviral Treatments, Characteristics, and Clinical Outcomes Published in Digestive Diseases and Sciences
06/29/2021Liver International Publishes Hepatocellular Carcinoma RWE Review
06/22/2021Target RWE Study Shows Significant Differences in Medication Use Among Older Patients with IBD Compared to Younger Patients
06/15/2021TARGET-NASH Study Finds Statins Underutilized in Patients with NAFLD and At-Risk of Heart Disease
05/25/2021Target RWE COVID-19 Data: Real-World Evidence Analysis Shows 3.6% of COVID-19 Hospitalized Patients Discharged Alive Required Readmission